Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a summary of its 2021 antiviral drug program so far this year, noting that all objectives in evaluating its proprietary DehydraTECH(TM) drug-delivery platform have been achieved. In addition, the company also discussed next steps. In short, the company stated thatit has successfully tested and released summary results on five different compounds from three antiviral drug classes, with results gathered that indicate up to a threefold increase in oral drug delivery into the bloodstream upon animal testing when processed with DehydraTECH. According to the announcement, the company has been able to determine whether DehydraTECH processing of compounds from leading classes of antiviral drugs for SARS-CoV-2/COVID-19, HIV/AIDS and other infectious diseases had the ability to exhibit evidence of superior oral absorption relative to controls. In addition, testing has shown whether DehydraTECH processing of those compounds could preserve expected viral inhibitory performance upon efficacy testing in infected mammalian cells. In addition, the company noted that DehydraTECH neither alters nor degrades drug molecules chemically, resulting in the creation of new molecular entities. Looking forward, the company’s drug-testing program will likely include larger in vivo efficacy evaluations in animals infected with SARS-CoV-2, HIV or other infectious viruses. The announcement noted that Lexaria is focused on a comprehensive, multipronged program designed to gather and evaluate proof-of-concept safety, efficacy and formulation/scalability feasibility data for potential pharmaceutical industry partners to evaluate for expanded, collaborative product development.

To view the full press release, visit https://cnw.fm/1kd1y

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Cannabis Terpenes Relieve Pain, Play Role in “Entourage Effect”

Cannabinoids are a range of compounds produced by plants in the cannabis family with THC, the main psychoactive component in marijuana, being the most abundant as well as the most well-known. Most of these compounds, including THC, have been found to have a variety of health benefits, with most of them producing minimal to zero psychoactive effects.

For quite a while, there has been a theory about how cannabis, when consumed as a whole, is much more effective compared to when the cannabinoids are taken separately. Dubbed the “entourage effect,” this theory states that the sum of the cannabis plant, including terpenes and flavonoids as well as cannabinoids is greater than its individual components.

A recent study from the University of Arizona Health Science has uncovered evidence to back this theory, especially regarding cannabis’ pain-relieving capabilities. The researchers found that using cannabinoids alongside terpenes had a much more impactful effect on pain, potentially providing individuals suffering from chronic pain a treatment option that would need fewer doses and result in fewer negative effects.

John Streicher, PhD, the study’s lead researcher and an associate professor of pharmacology at the College of Medicine in Tucson, Arizona, and a member of the UArizona Health Sciences Comprehensive Pain and Addiction Center, says the researchers wanted to see if they could boost THC’s “modest pain-relieving” abilities by leveraging the entourage effect. Terpenes, which are produced by many plants, not just cannabis, and are responsible for marijuana’s pungent aroma, provided interesting results.

The researchers found that cannabis terpenes mimicked cannabinoids when taken by themselves, leading to a moderate level of pain relief. Once they were used together with cannabinoids, their pain-relieving impact was boosted without any negative side effects. Since terpenes can be found in numerous plants, the researchers did not expect them to affect pain the way cannabinoids do, says Streicher, who noted that the researchers used four cannabis terpenes: linalool, beta-pinene, alpha-humulene and geraniol as well as a synthetic cannabinoid capable of stimulating the body’s cannabinoid receptors called WIN55,212-2.

Cannabinoids such as THC interact with the endocannabinoid system, binding to either CB1R or CB2R receptors. According to the researchers, the four terpenes they used attached to the CB1R receptors, with behavioral studies using mice proving that once the terpenes had interacted with the receptors, they caused three of the four classic cannabinoid effects. Those effects were reduced sensitivity to pain, reduced movement, lower body temperature and catalepsy.

Streicher hopes that the research may eventually lend a hand in the fight against the opioid crisis, especially in regard to cancer-related pain. By developing therapies that combine cannabinoids and terpenes, he would like to offer people suffering from different types of cancer-related pain a low-dosage, minimum-risk treatment option.

With the increasing availability of technologies such as the IoT dose-measuring devices being made by RYAH Group Inc. (CSE: RYAH), researchers could find it even easier to study how phtyocannabinoids, terpenes and other compounds affect human health.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Emergency Hospital Visits Related to Opioids See Temporary Decline After Cannabis Is Legalized

Since 1999, nearly 841,000 people have died from a drug overdose, with synthetic opioids being responsible for 72.9% of these deaths. The opioid crisis has taken hundreds of thousands of lives over the past two decades, and with people becoming increasingly aware of the long-term consequences of using opioids, there has been increased interest in alternative pain relievers. Cannabis is one such alternative, and as more than 30 states have legalized it for either medical or recreational use, more people have been abandoning opioids and turning to the controversial plant for pain relief.

There were, and still are, many objections to legalizing cannabis, with one of them being that it would be a gateway to opioid use. However, a recent study has found just the opposite: states that legalize recreational cannabis markets see a decline in opioid-related emergency department (“ED”) visits for six months. After studying data from Nevada, Maine, Massachusetts and California, researchers from the University of Pittsburg found that over a six-month period, there has been a 7.6% reduction in opioid-related ER visits compared to states that do not have adult-use cannabis markets.

Analysis by the University of Pittsburgh Graduate School of Public Health found that this decline was particularly prominent among men and people aged 25 to 44 years old. Although the decline was small, Coleman Drake, PhD, lead author of the study and assistant professor at Pitt Public Health’s Department of Health Policy and Management, says it isn’t a trivial feat. It may have been only for six months, but Drake observes that any decline in opioid-related emergency room visits is a welcome public health development.

Even if the effect of the recreational markets on ER visits stops, the study has provided evidence that cannabis is not a gateway to opioids use, as many cannabis prohibitionists feared. The study, which was published in “Health Economics,” looked at data concerning opioid-related ER visits from 29 states with Nevada, Maine, Massachusetts and California having legalized adult use cannabis and the other states acting as controls.

Cannabis has been informally used for years as a pain reliever, but the advent of cannabis laws has allowed researchers to study its medicinal properties more closely. According to the study’s abstract, recent evidence shows that recreational cannabis laws may be alleviating the opioid crisis by allowing adults suffering from chronic pain to turn to cannabis rather than opioids. Cannabis may also be used to treat symptoms of opioid withdrawal, although the study notes that the plant cannot directly treat opioid-use disorder. However, Drake cautions, cannabis laws aren’t enough to curb the effects of the opioid pandemic.

As companies such as Sonoma Biologics Corp. keep manufacturing high-quality medical cannabis, it is possible that an increasing number of patients with chronic pain may ditch opioids for cannabis, especially when the legalization drive succeeds in more parts of the country.

NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Advocates for Temperature-Fighting Cannabis to Beat Record Heat

Chalice Brands (CSE: CHAL) (OTCQB: CHALF), a consumer-driven cannabis company in the medicinal and recreational marijuana market segments, is building a strong presence in Oregon. This presence allows interested Oregonians to test the cannabis cooling theory captured in a Chalice magazine article titled “Cannabis Is Cool.” The theory states that: “Cannabinoids, compounds found in cannabis, can interact with the hypothalamus and endocannabinoid system and subsequently impact temperature regulation while also occupying the vanilloid receptor family (TRPA-1, TRPM8, etc.). . . . Thanks to our interest in cannabis, we know the vanilloid receptors alter our perception of heat and pain and, therefore when also engaged by cannabinoids, may numb our sensation of heat and feeling hot.” The article came as the West was experiencing record heat levels, with temperatures topping 100 degrees in California, Oregon, Arizona, Nevada and Utah. While Chalice calls for people to be reasonable and intelligent adults by making sure they drink water and finding shade or air conditioning, the company also offers this suggestion: “Beat the heat this summer with temperature-fighting cannabis. . . . If this is another excuse to consume a little bit more cannabis, we’ll take it!”

To view the full article, visit https://cnw.fm/jC82z

About Chalice Brands Ltd.

Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with 12 dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice Brands operates nationally through Fifth and Root and has operations in Oregon and California. Visit https://Investors.ChaliceBrandsLtd.com for regular updates.

NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://cnw.fm/CHALF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Hero Technologies Inc.’s (HENC) Business Strategy Reaffirmed as Trend Moves Toward Greenhouse Cultivation

Hero Technologies (OTC: HENC) has a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal conditions in greenhouses to enhance photosynthesis and produce large flowering plants. Thus, the trend toward greenhouse cultivation is welcome news for HENC. A recent article reads, “According to a recent five-year study of the cannabis industry, greenhouse production is a leading choice for cannabis cultivation companies (https://cnw.fm/R9t7G). The report, published by ‘Cannabis Business Times,’ reaffirms the business strategy of Hero Technologies.” It noted that greenhouse production continues to be the top tool for reducing the initial and operational costs for a 52-week production facility. “‘Nearly a third of greenhouse cultivators also report average production costs of less than $100 per pound of dried flower, compared to 11% of indoor cultivators.’ The trend toward greenhouse cultivation is understandable when looking at the bottom line. The report noted that, in 2020, the average cost to grow a pound of dried flower was $396 for warehouse or indoor cultivation sites, and more than $150 less ($233) to grow the same amount in a greenhouse.”

To view the full article, visit https://cnw.fm/W3w1X

About Hero Technologies Inc.

Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. Hero Technologies’ strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator (“MSO”). For more information about the company, visit www.HeroTechnologiesinc.com.

NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://cnw.fm/HENC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Significantly Enhanced Delivery of Colchicine

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. According to the update, the study demonstrated that DehydraTECH(TM)-enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from the company’s proprietary formulation and processing, resulting in significantly increased delivery. The study also examined absorption with two other antiviral drugs previously untested by Lexaria; however, the bloodstream delivery findings were unremarkable and further work is required should the company decide to pursue additional testing with the two drugs. Lexaria will likely focus on DehydraTECH-processed colchicine and other antiviral drugs it has tested given the superior results already demonstrated. The company will summarize and provide guidance on the 2021 antiviral program to date and its planned next steps in an imminent press release.

To view the full press release, visit https://cnw.fm/uHnD7

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated, since 2016 with cannabinoids and nicotine, the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes. DehydraTECH is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and approximately 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CBD Tincture vs. CBD Oil: How Do They Differ?

Unless you have been living under a rock for the past couple of years, you have most likely heard of CBD (cannabidiol), even in passing. It is one of more than 100 cannabinoids produced by plants in the cannabis family, and preliminary research coupled with anecdotal evidence claims that it has plenty of potential medical benefits without making users feel “high.” As such, a growing number of people have turned to hemp-derived CBD to alleviate a wide variety of health issues, with CBD oils and tinctures being among the most popular forms of consumption.

While both products are similar in that CBD is the main ingredient, they differ greatly based on how they are produced and consumed, and, in some cases, even how quickly their effects take hold. CBD oils are created by extracting cannabidiol from a hemp plant’s flowers, seeds and stalks then suspending the CBD within a carrier oil, resulting in a potent, oil-based product that often includes proteins and fatty acids, as well as essential vitamins plus proteins from the hemp plant. On the other hand, CBD tinctures use alcohol rather than oil as a base, resulting in a relatively low potency product suspended in 60–70% distilled alcohol.

CBD oils use oil bases such as coconut oil, MCT oil, vegetable glycerin or hemp seed oil, and because of this, they usually have a short shelf life. On the bright side, the fact that they are suspended in oils makes it much easier for one’s body to assimilate and absorb them. Note that the rate of absorption will depend on how you consume the CBD oil, with CBD edibles taking much longer to digest and kick in when compared to vaping. Additionally, they tend to be much more potent than tinctures, and users will find just two or three teaspoons of CBD oil per day more than enough. They have a bitter, unpleasant taste when consumed orally, but you can get rid of this taste by infusing the oils in edibles.

CBD tinctures are quite different, with most CBD tinctures containing a mixture of glycerin, or peppermint/cinnamon oil and alcohol. They are usually consumed sublingually, meaning placed under the tongue, and they come in a variety of flavors, including peach, chocolate and vanilla. Due to the alcohol base and mode of consumption, a CBD tincture has a much higher bioavailability compared to cannabidiol oil, and using water-soluble CBD to cook with CBD tinctures makes the absorption rate even higher. Tinctures also have a longer shelf life, and their effects tend to kick in much faster. Vaping CBD oil will also result in quicker effects; however, users are cautioned to choose high-quality vapes to stay safe.

Regardless of how they are consumed and how long it will take for the effects to kick in, both CBD oils as well as tinctures possess the same therapeutic effects. Both offer discreet consumption methods, although tinctures will kick in faster than oils, so the choice between oils and tinctures will ultimately depend on preferences. However, make sure you consult a doctor before consuming a CBD product, especially if you are pregnant or on medication.

Needless to say, companies such as Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), which are involved in the extensive cultivation of hemp and manufacture of CBD products, make both oils and tinctures, among other products, so that each consumer can choose what will best serve their needs.

NOTE TO INVESTORS: The latest news and updates relating to Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) are available in the company’s newsroom at http://cnw.fm/PACR

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Congressional Legislators Advance Spending Bills Containing Protections for Universities, Medical Cannabis Programs

The cannabis industry has been in a tense state of anticipation since President Joseph Biden came into office. Although Biden has made it clear he supports medical cannabis and giving states the ability to do what they want, he doesn’t support federally legalizing recreational cannabis. Conversely, Senate Majority Leader Chuck Schumer has said he is currently working on cannabis legislation that he says he will advance with or without the president’s approval; however, reform advocates and industry stakeholders would like to see that legislation come sooner rather than later.

As such, cannabis reform proponents and industry stakeholders will be happy to hear that Congressional lawmakers have again included several cannabis-related provisions in spending legislation, including protections for states that have launched medical cannabis programs. The past couple of weeks have seen lawmakers pass spending legislation for fiscal year 2022 and attached reports that will have significant impact on the state legal cannabis sector moving forward. Last week the House Appropriations Committee approved two bills in subcommittee that contain language preventing the Justice Department from intervening in state-legal medical cannabis programs that use tax dollars and that protect state legal hemp programs from federal interference.

One measure that has been included in federal legislation since 2014 prevents the Justice Department from using tax dollars to interfere with state-legal medical cannabis programs. However, it is unclear whether lawmakers will include and champion an amendment that would offer the same protections to state-legal recreational markets. While the House approved such amendments in 2019 and 2020, those amendments weren’t attached to the final bills that were sent to Donald Trump’s desk, who was president at the time, because they had not been included in the Senate versions of the bills.

Another longstanding provision, which was included in the Commerce, Justice, Science and Related Agencies (“CJS”) spending bill, would prevent the Department of Justice and the Drug Enforcement Administration from meddling in state-legal hemp programs. Specifically, the provision states that none of the funds provided by the spending bill it is attached to can be used to interfere with hemp programs legitimized by section 7606 of the Agricultural Act of 2014. Furthermore, another attached provision says that states and localities that insist on maintaining policies that allow no-knock warrants for drug-related cases will be ineligible for certain law enforcement grants from the federal government.

Additionally, members of the House Labor, Health and Human Services, Education and Related Subcommittees advanced a spending bill that contained language that would prevent the Department of Education from denying institutions that research or plan to research marijuana funding.

It would be even better for the entire cannabis industry with all its actors, including The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER), if Congress moved a step higher and initiated the legalization of cannabis federally so that companies can transact without needless hurdles such as the challenges in securing banking services.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – The Alkaline Water Company Inc.’s (NASDAQ: WTER) (CSE: WTER) Alkaline88 Water to be Available in Over 800 Gyms Nationwide via Distribution Agreement

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products sold under the brand names Alkaline88(R), A88 Infused(TM) and A88CBD(TM), today announced that it has secured a distribution agreement with Premier Distribution Services (“PDS”). Per the terms of the agreement, PDS will distribute the entire Alkaline88 bottled water to over 800 gyms, personal training studios, smoothie bars and sports nutrition stores across the country. “This is a wonderful opportunity for the company as Premier Distribution Services will be carrying all of our Alkaline88(R) bottled waters in coolers across the country. It will help us introduce and drive the trial of our new 2-liter, aluminum, and flavor-infused SKUs. It will also allow for the chilled on-premise purchase of the country’s favorite premium gallon water, Alkaline88,” The Alkaline Water Company President and CEO Ricky Wright stated in the news release. “This is a great partnership for both parties. PDS’s clients will be able to offer health-conscious gym-goers the Smooth Hydration(TM) of Alkaline88, the Clean Beverage(TM). While PDS continues to execute their growth plan, we’ll expand with them in health and fitness venues across the country. As we plan to mobilize our first broadly-distributed traditional marketing campaign with Shaquille O’Neal later this year, more and more people will be looking for our brand as their go-to choice to rehydrate during their workouts. The timing couldn’t be any better.”

To view the full press release, visit https://cnw.fm/jwwbT

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company (NASDAQ and CSE: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts our trademarked label ‘Clean Beverage.’ Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in six unique all-natural flavors, with new flavors coming soon. In 2021, The Alkaline Water Company was pleased to welcome Shaquille O’Neal to its board of advisors and to serve as the celebrity brand ambassador for the Alklaine88(R) and A88 Infused(TM) brands. To purchase Alkaline88(R) and A88 Flavor Infused products online, visit www.Alkaline88.com. To learn more about The Alkaline Water Company, visit www.TheAlkalineWaterCo.com or connect with the company on Facebook, Twitter, Instagram, or LinkedIn.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is the global innovator behind the patented DehydraTECH(TM) technology. DehydraTECH increases the effectiveness of lipophilic (fat-soluble) drugs and active ingredients and improves the way active pharmaceutical ingredients enter the bloodstream. It speeds up delivery, increases bioavailability, increases brain absorption, improves drug potency, reduces drug administration cost and masks unwanted taste. A recent article reads, “Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats. The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings.” Led by an experienced management team, Lexaria is focusing its ongoing research and development efforts on developing product candidates across several key billion-dollar segments: oral cannabinoids, antivirals, oral mucosal nicotine, human hormones, ibuprofen and Naproxen, and vitamin D3. The antivirals segment, for example, is “an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.”

To view the full article, visit https://cnw.fm/RPuwh

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. DehydraTECH has repeatedly demonstrated, since 2016 with cannabinoids and nicotine, the ability to increase bioabsorption by up to 5 to 10x, reduce onset time of one to two hours to minutes, and mask unwanted tastes; DehydraTECH is also planned to be further evaluated for orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.